Latest News in the pharma Industry
Policy & Regulation
HHS Launches New Initiative to Strengthen Primary Care
29 Sep 2011
Under the new initiative, Medicare will work with commercial and state health insurance plans to offer additional support to primary care doctors who better coordinate care for their patients.
Read more
Novartis Receives Japanese Regulatory Approval for Two Innovative Therapies
28 Sep 2011
The Japanese regulators have approved Novartis' once-daily Gilenya (fingolimod) 0.5mg and Illaris (canakinumab) subcutaneous injection 150mg in the Japanese market.
Read more
India Releases Guidelines for Conservation & Development of Medicinal Plants
28 Sep 2011
The scheme released by India's Department of Ayush aims to promote availability of quality plant based raw material.
Read more
Boehringer Ingelheim Receives EU Approval for Viramune Once-daily Formulation
28 Sep 2011
Boehringer Ingelheim has received European approval for its once-daily Viramune tablets for HIV treatment.
Read more
Eisai Receives Canadian Approval of Banzel as Adjunctive Treatment for Severe Epilepsy Disorder
26 Sep 2011
Canadian regulators have given approval of Banzel for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome.
Read more
Tokai Secures Financing to Advance Cancer Drug Study
26 Sep 2011
Tokai Pharmaceuticals has received $23m funding in a Series D3 financing to support its ongoing clinical development of galeterone.
Read more
Remicade Approved to Treat Ulcerative Colitis in Children Older Than 6 Years
26 Sep 2011
Janssen's Remicade has been approved by FDA to treat moderately to severely active ulcerative colitis in children older than 6 years who have had inadequate response to conventional therapy.
Read more
FDA Approves Soliris for Rare Pediatric Blood Disorder
26 Sep 2011
The FDA has approved Soliris to treat patients with atypical Hemolytic Uremic Syndrome that can lead to kidney failure and is also associated with increased risk of death and stroke.
Read more
EMA Recommends Restricting Use of Multaq
23 Sep 2011
Due to an increased risk of liver, lung and cardiovascular adverse events, Multaq should only be prescribed after alternative treatment options have been considered.
Read more
EMA Starts Review of Orlistat-containing Medicines
23 Sep 2011
The EMA is reviewing relevant data on the risk of hepatotoxicity of orlistat-containing medicines and will issue an opinion on whether or not the marketing authorisations should be revoked, suspended or changed.
Read more
EMA Recommends Discontinuation of Vimpat Syrup
23 Sep 2011
The recommendation follows the voluntary recall of Vimpat 15mg/ml syrup on 15 September 2011. The recall was initiated because of a quality defect in some batches leading to uneven distribution of the active substance lacosamide in the syrup.
Read more
NIH to Facilitate License Agreements of Medical Technologies
21 Sep 2011
NIH is reducing both the cost and paperwork requirements for start-up companies to obtain an exclusive option agreement to license the extensive patents and patent applications from research laboratories.
Read more